Coeptis Therapeutics, Inc. Proceeds from Convertible Debt
Coeptis Therapeutics, Inc. reported Proceeds from Convertible Debt of $1.50 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2021-11-15
- 2021-09-30: Proceeds from Convertible Debt 9 month $1.50M.
| Period end | Proceeds from Convertible Debt 9 month |
|---|---|
| 2021-09-30 | $1.50M 10-Q · filed 2021-11-15 |